Elan and Biogen Idec submit for Antegren approval

Pharmaceuticals giant Elan and drug developer Biogen Idec have announced plans to submit to the European Agency for the Evaluation of Medicinal Products (EMEA) for approval of Antegren, a treatment for multiple sclerosis (MS).

The decision came after discussions with European regulatory officials, based on one-year data from ongoing drug trials.